Search Results - clinical+and+disease+specializations+%3e+oncology+%3e+pancreatic+cancer

21 Results

Sort By:

CRISPR/Cas9 and Tumor-Specific Guide RNAs as a Specific and Selective Cancer Cell Killing Biologic Platform

Value Proposition:Specific targeting of mutations can treat any cancer with the specified mutations.Selective cell killing spares healthy tissue while eliminating cancer cells. Pan-cancer efficacy as guide RNAs are developed to target a wide breadth of cancer-specific mutations.Lack of protospacer adjacent motif (PAM) sites in healthy host cells prevents...

Published: 6/28/2024 | Inventor(s): James Eshleman, Selina Shiqing Teh, Kirsten Bowland, Nicholas Roberts

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools > Nucleic Acids

Identification of RNF43 Mutations in Pancreatic Cysts

Unmet Need· One third of diagnoses for surgical resection of pancreatic cysts are incorrect, leading to unnecessary surgery, medical risk, and high costs (Hammel, 2002). The current standard of care for determining pancreatic cyst type is based solely on symptom progression and imaging criteria, and histopathological analysis is only available...

Published: 6/27/2024 | Inventor(s): Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Jian Wu, Anirban Maitra, Ralph Hruban, Marco Dal Molin

Keywords(s): Cancers, Cloning Reagents, Discovery/Research Tools, Disease Indication, Nucleotide, Pancreatic Cancer, Research Reagent, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Research Tools > Nucleic Acids, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers

Large-scale Epigenomic Reprogramming Links Anabolic Glucose Metabolism to Distant Metastasis during the Evolution of Pancreatic Cancer Progression

Unmet NeedPancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer death in the western world by 2020. Subclonal populations that emerge and drive metastatic progression of the disease are associated with high mortality rates among patients. Blocking the tumorigenic potential of metastatic sites is key to improving...

Published: 6/27/2024 | Inventor(s): Andrew Feinberg, Xin Li, Christine Iacobuzio-Donahue, Oliver McDonald

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer

EXoO-Tn Tag-n-Pin the Pan-Carcinoma Tn Antigen in Human Proteome

Unmet NeedAberrant glycosylation has been implicated as a mechanism of cancer progression. Accordingly, identifying the differences in glycan structures within clinical specimens, cancer, and normal cells provides a unique opportunity to identify new biomarkers and therapeutic targets. In particular, Tn antigen (Tn) is a simple O-linked glycan structure...

Published: 6/28/2024 | Inventor(s): Hui Zhang, Weiming Yang

Keywords(s): Analytical Method, Assay, Cancers, Clinical Diagnostics, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics (Old), In Vitro Research Tool, Pancreatic Cancer, Pancreatic ductal adenocarcinoma

Category(s): Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics > Biomarkers

Most Pancreatic Ductal Adenocarcinomas have Detectable Telomere Fusions and their Detection in Pancreatic Cyst Fluids Predicts the Grade of Dysplasia of Intraductal Papillary Mucinous Neoplasms

Unmet Need Physicians must determine whether patients with cystic tumors of the pancreas will be operated on or receive further imaging and monitoring. Biomarkers that can inform the physician of the state of progression of the tumor, as well as predict the neoplastic nature of the cyst, would be valuable for determining treatment course. Specifically,...

Published: 6/27/2024 | Inventor(s): Michael Goggins, Tatsuo Hata

Keywords(s): Assay, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Pancreatic Cancer

Semaphorin 3D and Plexin D1 as New Therapeutic Targets for Pancreatic Cancer Treatment

Unmet Need: Most patients with pancreatic ductal adenocarcinoma (PDA) present with metastatic disease at the time of diagnosis or will recur with metastases after surgical treatment. Technology Overview: Semaphorin-plexin signaling mediates the migration of neuronal axons during development and of blood vessels during angiogenesis. The expression of...

Published: 6/27/2024 | Inventor(s): Lei Zheng

Keywords(s): Biomarker, Cancer Cells, Cancers, Cell Model, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Mechanism-of-action Biomarker, Pancreatic Cancer, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

Development of magnetic bead-based multiplex immunoassays of serum biomarkers for the early detection of pancreatic cancer

Pancreatic cancer is the 4th leading cause of cancer death in the United States. The majority of patients present with unresectable disease leading a median survival of 6 months and an overall 5-year survival of < 5%. The early detection of this disease is critical because surgery at an early stage is the most promising therapy that could greatly...

Published: 6/27/2024 | Inventor(s): Jin Song, Zhen Zhang, Daniel Chan

Keywords(s): Adenocarcinoma, Assay, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Sample Prep Method

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

PALB2 Gene Mutations Identify Susceptibility to DNA Damaging Agents

PALB2 Gene Mutations Identify Susceptibility to DNA Damaging AgentsJHU Ref #: C10869Unmet NeedPancreatic cancer is predicted to be the second leading cause of cancer-related death by 2030 (Siegel et al., 2020). However, many patients present with advanced disease, and typical broad-spectrum chemotherapeutic treatments are often insufficient. Precision...

Published: 6/27/2024 | Inventor(s): Ralph Hruban, Bert Vogelstein, Kenneth Kinzler, Victor Velculescu, Scott Kern, Sian Jones, Michael Goggins, Manuel Hidalgo, Alison Klein, James Eshleman, Donald Parsons

Keywords(s): Biomarker, Clinical Diagnostics, In Vitro Diagnostics, Risk Stratification

Category(s): Technology Classifications > Computers, Electronics & Software > Precision Medicine Tools, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Computers, Electronics & Software, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Precision Medicine Tools

Activators of Myosin II for Modulating Cell Mechanics

C12770: Novel Panel of Myosin II Activators for Disease Therapy and Tissue EngineeringNovelty:A panel of myosin II activators developed to treat disease and useful for tissue engineering in regenerative medicine.Value Proposition:Changes in cellular mechanics due to impaired activity of myosin II, a motor protein essential for cell division, motility,...

Published: 6/27/2024 | Inventor(s): Douglas Robinson, Alexandra Surcel, Win Pin Ng, Caren Freel Meyers

Keywords(s): Agonists/Promoters, Cancers, Disease Indication, Non-novel, Pancreatic Cancer, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Medical Devices > Regenerative Medicine, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for Cancer Therapy

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for cancer therapyJHU REF: C13142 Invention novelty: An improved glutaminase (GLS) inhibitors delivery system to enhance efficacy and prolong glutaminase inhibitor drug levels in tumor for improve treatment of pancreatic cancer. Value Proposition: Currently available glutaminase inhibitors...

Published: 6/27/2024 | Inventor(s): Barbara Slusher, Jie Fu, Justin Hanes, Qingguo Xu, Quy Hoa Le Thi, Takashi Tsukamoto

Keywords(s): Adenocarcinoma, Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Non-novel, Off-the-shelf, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

1 2 3